Theranostics Australia is proud to be a Supporting Partner of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, April 20 – 24 2018 >> https://goo.gl/RaJBas
Theranostics Australia’s A/Prof Nat Lenzo will be presenting at Perth Urology Clinic’s GP Urology Masterclass on “theranostics” as a non-surgical cancer therapy. A/Prof Lenzo joins speakers from Perth Urological Clinic, Perth Radiology Clinic, Oncology West and GenesisCare. Topics include: female urology and OAB, urological stone disease, surgical andrology, male LUTS and BPH, urological oncology and non-surgical cancer therapy.
SCHOLARSHIP OPPORTUNITY: Telix Pharmaceuticals has partnered with Memorial Sloan Kettering Cancer Centre (MSKCC) to create a fully-funded place for an Australian undergraduate* to attend the Molecular Imaging Summer Program (MISP) in New York. (*subject to specific criteria). Read More/Apply here >> https://goo.gl/VX2BR4 **Applications can be sent directly to email@example.com up until the (extended) deadline of Feb 9th.**
Novartis AG (NVS) announced that Advanced Accelerator Applications (AAA), a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application or NDA for Lutathera, a treatment for somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), in adults. Read More>> https://goo.gl/AChzVF & https://goo.gl/kgZYSL
Christmas Closure: Theranostics Australia will be closed from the 23rd of December 2017 and will reopen on Monday 8th of January 2018.
Advanced Accelerator Applications S.A. (AAA) announced in AUG17 that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera). Lutathera is the brand name for the radiologic used in Peptide Receptor Radionuclide Therapy (PRRT). The FDA has set an action date of Jan 26, 2018. Read more >>> https://goo.gl/sjURwh (2/2)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eleven medicines for approval at its July 2017 meeting. This included Lutathera (lutetium [177Lu] oxodotreotide), an orphan drug for the treatment of well differentiated gastro-entero-pancreatic neuroendocrine tumours. (1/2) Read More >> https://goo.gl/cRrRpb
The OPS-201 trial has now commenced in Perth. This IPSEN sponsored trial involves the use of Lutetium-177 OPS-201 for treatment of progressive metastatic neuroendocrine tumours (NETs). Theranostics Australia is one of several sites worldwide currently recruiting (together with Peter Mac in Melbourne, Royal Free in London and Memorial Sloan Kettering in New York).
This agent binds to both activated and unactivated somatostatin receptors which are upregulated on these tumours. There is far higher binding via this mechanism than standard octreotate.
The protocol involves 3 cycles 8 weeks apart of intravenous Lu-177 OPS-201. All patients will have baseline Ga-68 octreotate imaging performed.
The treatment is available for all NET patients with progressive metastatic disease including gastric and pancreatic NETs, pulmonary carcinoids, paraganglionomas and phaeochromacytomas.
Patients who have previously had Lu-177 octreotate are not eligible. Patients may have had any other treatment including chemotherapy, radiotherapy or SSTR analogues.
Costs of all tests, treatment and follow up is covered by Ipsen. The study is open to all patients – public or private.
If you would like further information on the trial or would like to refer a patient for screening assessment please contact us via email: firstname.lastname@example.org or phone: +61 8 9091 1081.
Theranostics Australia, in collaboration with other respected industry partners, will work with PhD students and early career researchers on innovative projects at an $8.5m state-of-the-art research hub to be established at The University of Queensland (UQ).
The centre will provide firsthand training to the next generation of scientists, who will expand the boundaries of biomedical imaging to improve healthcare.
The Industrial Transformation Training Centre for Innovation in Biomedical Imaging Technology (CIBIT) will prepare new scientists to work in industry and develop ‘smart’ biotechnology and biomedical imaging techniques.
The UQ Centre for Advanced Imaging (CAI) Director, Professor David Reutens, said the $8.5m research will be funded by a $4.7m Australian Research Council (ARC) grant and $3.8m in cash and in-kind contributions from industry partners.
“It will play a leading role in the future of biomedical imaging,” he said.
“Biomedical imaging has been one of the most important advances in the history of medicine.
“It allows medical professionals to determine the location, nature and extent of disease with high accuracy and sensitivity, and has become an integral part of modern health care.
“This new centre will train industry-ready scientists to lead research into faster, more accurate and more cost-effective diagnostic imaging.”
The centre’s industry driven research will work to overcome barriers in the development and application of novel diagnostics, therapeutics and theranostics for important diseases like cancer.
Sixteen PhD students and five early career researchers will work on projects with industry partners.
The centre will involve researchers from across UQ, including the Centre for Advanced Imaging (CAI), UQ Business School (UQBS), the Australian Institute for Bioengineering and Nanotechnology (AIBN), the UQ Diamantina Institute (UQDI) and the School of Mathematics and Physics (UQSMP).
Industry partners include Siemens Healthcare Pty Ltd, Clarity Pharmaceuticals Pty Ltd, Minomic International Ltd, Inter-K Peptide Therapeutics Ltd, Theranostics Australia Pty Ltd, Beijing Genomics Institute, Brisbane Veterinary Specialists Centre, Uniting Care Medical Imaging, and Red Radiology Pty Ltd.
The centre builds upon previous investments in CAI and the National Imaging Facility (NIF) from the Queensland Government and the Commonwealth Government’s contributions to the NIF through the National Collaborative Research Infrastructure Strategy (NCRIS) and the Education Investment Fund (EIF).
Original Media Release by the University of Queensland: http://bit.ly/2toXaHR